Skip to main navigation Skip to search Skip to main content

Sulfatide inhibits fibroblast growth, activation and oxidative stress induced by ectopic insulin

Allan Roeske-Nielsen, Jan-Eric Månsson, Hasim Tekin, Klaus Rieneck, Klaus Bendtzen, Karsten Buschard*

*Corresponding author for this work
1 Citation (Scopus)

Abstract

AIM: To study the effect of sulfatide on gene expression and proliferation of human primary fibroblasts induced by insulin, insulin-like growth factor-1 and human growth hormone.

MATERIALS AND METHODS: Human primary fibroblasts were exposed to 1, 3 and 30 μM of sulfatide or its precursor galactosylceramide (GalCer). Proliferation was determined by 3 H-thymidine incorporation and gene expression via microarray analysis.

RESULTS: Sulfatide and GalCer reduced the growth rate of fibroblasts by 32%-82% when exposed to 0.5 nM insulin. After challenge with 120 μM of H2 O2 , sulfatide reduced membrane leakage. Fibroblast gene expression was altered by sulfatide in gene pathways associated with cell cycle/growth, transforming growth factor-β function, and encoding of proteins involved in intracellular signalling. NFKBIA, a key control element in NF-кB regulation, was decreased 2-fold by sulfatide.

CONCLUSIONS: Sulfatide strongly inhibits fibroblast growth. We therefore suggest the addition of sulfatide to injectable commercial insulin formulations, which would reduce adverse fibroblast growth and improve well-being in patients with diabetes.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume25
Issue number9
Pages (from-to)2514-2525
Number of pages12
ISSN1462-8902
DOIs
Publication statusPublished - Sept 2023

Keywords

  • beta cell devices
  • fibroblasts
  • sphingolipids
  • sulfatide
  • type 1 diabetes

Fingerprint

Dive into the research topics of 'Sulfatide inhibits fibroblast growth, activation and oxidative stress induced by ectopic insulin'. Together they form a unique fingerprint.

Cite this